Market Analysis: Global Blood Cancer Drug Market 

Global blood cancer drug market is expected to rise gradually to an estimated to register a healthy CAGR of 10.5 % in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Growing cases of hematology-oncology disorders and progressively focusing on innovation of novel therapies are the key drivers for market growth.

Few of the major competitors currently working in the global blood cancer drug market are Eli Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson Services. Inc., AbbVie Inc., Amgen Inc. , Bayer AG, Pfizer Inc., AstraZeneca, CELGNE CORPORATION, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA, Sumitomo Dainippon Pharma Co., Ltd, Otsuka Holdings Co., Ltd, Astellas Pharma Inc. and many others..

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-cancer-drug-market

Market Definition: Global Blood Cancer Drug Market 

Blood cancer is life threatening oncology disorder in which cancer start growing in the bone marrow, where blood is produced. These tumors prevent the blood from functioning. The patients with blood cancer experience abdominal pain, bone pain, weight loss, dark spots, excessive or easy bruising and weakness. According to the statistic published in American Cancer Society 2019, it is estimated that over 8,110 cases are diagnosed with Hodgkin lymphoma in the United States in this current year. It is more prevalent in teenagers aged 15 to 19 years. Growing incidence of Hodgkin lymphoma worldwide and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Market Drivers

Rise in the incidence and prevalence rate of the disease will drive the growth of the market
Rise in the government and non-government investment in the research and development
Accelerating the demand of novel therapies and treatment
Increases in effectiveness of drugs for the treatment of hematology-oncology disorders

Market Restraints

Patent expiry of blockbuster drugs will result in generic and biosimilar competition
Effective treatment is either unavailable or costly
Inadequate knowledge of blood cancer in developing countries
Segmentation: Global Blood Cancer Drug Market 

By Type

Leukemia
Leukemia Lymphocytic Leukemias
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Myeloid leukemias
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Others
Myeloprolifeative Neoplasms
Systemic Mastocytosis
Hairy Cell Leukaemia (HCL)
Lymphoma
Non-Hodgkin Lymphoma
Hodgkin Lymphoma Myeloma
Typical Myeloma
Bence Jones Myeloma
Non-Secretory Myeloma
Immunoglobulin M–Producing Multiple Myeloma

By Therapy Type

Chemotherapy
Immunotherapy
Radiation therapy
Targeted Therapy

By Treatment

Medication
Blood Transfusion
Surgery
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation
By Mechanism of Action Type Proteasome Inhibitor
Bortezomib
Rituxima Kinase Inhibitor
Imatinib mesylate
Midostaurin
Gilteritinib
B-Cell Lymphoma-2 (BCL-2) Protein Inhibitor
Venetoclax
Isocitrate Dehydrogenase-1 (IDH1) Inhibitor
Ivosidenib
Enasidenib
Hedgehog Pathway Inhibitor
Glasdegib
Anti-CD20 Antibody
Rituximab
Ibritumomab

By Route of Administration

Oral
Injectable
Intramuscular
Subcutaneous
Intra-arterial
Intravenous

By End users

Hospitals
Homecare
Specialty Clinics
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia,
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-blood-cancer-drug-market

Key Developments in the Market:

In May 2019, AbbVie Inc. announced that they have received approval from FDA for Venclexta (venetoclax) which is an oral selective B-cell lymphoma-2 (BCL-2) protein inhibitor in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia. With the approval of Venclexta expanded the company’s portfolio in therapeutic area of oncology
In March 2018, Novartis AG received the FDA expanded label approval of Tasigna (nilotinib), a kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) in pediatric patients of age one year or older. This approval broaden the clinical indication of Tasigna
Competitive Analysis: Global Blood Cancer Drug Market 

Global blood cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of blood cancer market for global Europe, North America, Asia-Pacific, South America and Middle East & Africa.